Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: LASS2 enhances chemosensitivity to cisplatin by inhibiting PP2A-mediated β-catenin dephosphorylation in a subset of stem-like bladder cancer cells

Fig. 6

A combination of AAV-LASS2 and XAV939 overcomes cisplatin resistance in bladder cancer. A Selected chemoresistant patients for establishing PDX models. B A diagram illustrating the experiments of the PDX models. C–E Tumor growth curves of PDX tumors with the indicated treatments. F Survival rates of mice with the indicated treatments. G Representative images and H&E staining of PDX tumors with the indicated treatments. H, I Apoptosis assay by TUNEL staining of the indicated PDX tumors. J, K Immunohistochemistry staining of LASS2 in the indicated PDX tumors. L Immunofluorescent staining of β-catenin in the indicated PDX tumors. M Percentage of the CD44+ALDH1A1+ subpopulation in the indicated PDX tumors

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us